Whither Teva Pharmaceuticals (TEVA)?
After weeks of anticipation, the drug maker is starting a large-scale reorganization that involves 14,000 layoffs, or 25 percent of its workforce; closing or selling a “significant” number of 80 manufacturing plants; repricing or discontinuing some generics; closing or selling some R&D facilities and reviewing all R&D programs; and suspending dividends on ordinary shares and annual bonuses this year.
About the Author Reprints
